Date/Time: Saturday, March 18, 2023 - 5:00 PM to 6:30 PM
Log in to Add to My Schedule

Description:

Subchondral bone as well as bone morphology play important roles in the pathophysiology of osteoarthritis (OA). Subchondral trabecular bone structure, bone marrow and the calcified interface between bone and cartilage are important contributors to joint health and studies have shown that abnormalities of these tissues can accelerate progression of osteoarthritis. Abnormal bone morphology and shape, such as cam type morphology of the femoral head-neck junction also directly contribute to degenerative change of the entire joint. In the last 2 decades significant progress has been made in non-invasively characterizing bone abnormalities in OA through imaging. Imaging modalities have been refined and analysis techniques have been optimized to quantify bone structure and shape. Radiographs have been used to measure 2D bone shape, subchondral bone density and structure; these measures have been shown to predict progression of degenerative disease. Computed Tomography and high resolution peripheral Quantitative Computed Tomography have provided tools to calculate 3D bone shape and high spatial resolution imaging to analyze subchondral bone architecture. Magnetic Resonance Imaging not only allows to measure subchondral bone architecture, but it also provides technologies that can assess the calcified cartilage layer through ultrashort echo time imaging as well as the composition of the bone marrow, which is involved in OA incidence and progression. These technologies may help to better predict disease and also potentially monitor novel treatments. More recently artificial intelligence-based algorithms have been applied to these imaging technologies to further understand the pathogenesis of OA and drivers of OA progression.

Abstract(s):

• O-38
  THE ASSOCIATION BETWEEN STATISTICAL SHAPE
  VARIATIONS OF THE HIP AND THE DEVELOPMENT
  OF RADIOGRAPHIC HIP OSTEOARTHRITIS WITHIN 8
  YEARS OF FOLLOW-UP: DATA FROM 17,738 HIPS IN THE
  WORLD COACH CONSORTIUM.
  M. M. van Buuren1, F. D. Boel1, N. S. Riedstra1, H. Ahedi2, V. Arbabi3, N. K.
  Arden4, S. M. Bierma-Zeinstra1, C. G. Boer1, F. M. Cicuttini5, T. F. Cootes6,
  D. T. Felson7,6, W. P. Gielis3, G. Jones2, S. Kluzek8, N. E. Lane9, C. Lindner6,
  J. Lynch10, J. B. van Meurs1, A. E. Nelson11, M. C. Nevitt10, E. H. Oei1, J.
  Runhaar1, T. D. Spector12, J. Tang1, H. Weinans3,13, R. Agricola1; 1Erasmus
  Univ. Med. Ctr. Rotterdam, Rotterdam, Netherlands, 2Univ. of Tasmania,
  Hobart, Australia, 3Univ. Med. Ctr. Utrecht, Utrecht, Netherlands, 4Univ. of
  Oxford, Oxford, United Kingdom, 5Monash Univ., Melbourne, Australia,
  6Univ. of Manchester, Manchester, United Kingdom, 7Boston Univ. Sch. of
  Med., Boston, MA, 8Univ. of Nottingham, Nottingham, United Kingdom,
  9Univ. of California, Davis, Davis, CA, 10Univ. of California, San Francisco,
  San Francisco, CA, 11Univ. of North Carolina, Chapel Hill, NC, 12King’s Coll.,
  London, United Kingdom, 13Technical Univ. Delft, Delft, Netherlands

  O-39
  WHAT DO RADIOGRAPHIC MINIMUM AND FIXEDPOSITION
  JOINT SPACE WIDTH MEASURE? A
  COMPARISON OF RADIOGRAPHIC AND MRI MEASURES
  FROM THE OSTEOARTHRITIS INITIATIVE
  A. Brett1,2, M. Bowes2, P. G. Conaghan3; 1Stryker, Austin, TX, 2Imorphics,
  Manchester, United Kingdom, 3Univ. of Leeds, Leeds, United Kingdom

  O-40
  PATTERNS OF OA DEVELOPMENT ON MRI IN HIGH-RISK
  WOMEN WITH OVERWEIGHT AND OBESITY AND THE
  ROLE OF BONE MARROW LESIONS
  J. Runhaar, E. Macri, E. Oei, S. Bierma-Zeinstra; Erasmus MC, Rotterdam,
  Netherlands

  O-41
  THREE-DIMENSIONAL ULTRASOUND FOR
  QUANTITATION OF SYNOVIAL TISSUE VOLUME IN KNEE
  OSTEOARTHRITIS
  R. S. Dima1, T. Birmingham1, C. du Toit1, J. Polus1, A. Fenster1, C. Appleton2;
  1Western Univ., London, ON, Canada, 2Schulich Sch. of Med. and Dentistry,
  London, ON, Canada

  O-42
  HISTOLOGICAL VALIDATION OF THE TEXTURAL
  FEATURES FROM QUANTITATIVE MRI FOR
  DETERMINATION OF CARTILAGE DEGENERATION
  V. Juras1, S. Toegel1,2,3, B. Hager1,4,5, M. Schreiner1, V. Janacova1, R.
  Heule6, D. Laurent7, F. Saxer7, O. Bieri8, E. Raithel9, P. Szomolanyi1,10, C.
  Fuchssteiner1, W. J. Weninger1, R. Windhager1, S. Trattnig1,4,11; 1Med.
  Univ. of Vienna, Vienna, Austria, 2Ludwig Boltzmann Inst. for Arthritis and
  Rehabilitation, Vienna, Austria, 3Karl Chiari Lab for Orthopaedic Biology,
  Vienna, Austria, 4CD Lab. for MR Imaging Biomarkers (BIOMAK), Vienna,
  Austria, 5Ludwig Boltzmann Inst. for Experimental and Clinical Traumatology,
  Vienna, Austria, 6Univ. Children’s Hosp., Zurich, Switzerland, 7Novartis
  Inst.s for BioMed. Res., Basel, Switzerland, 8Univ. of Basel Hosp., Basel,
  Switzerland, 9Siemens Hlth.care GmbH, Erlangen, Germany, 10Slovak
  Academy of Sci., Bratislava, Slovakia, 11Karl Landsteiner Society, Vienna,
  Austria

Speaker(s):

• Thomas Link, MD, PhD